Recombinant Cynomolgus Monkey PD-L1/B7-H1 His Protein, CF

Recombinant Cynomolgus Monkey PD-L1/B7-H1 His Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: PD-L1/B7-H1

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1, 2). Mature cynomolgus B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 30 aa cytoplasmic domain. Within the ECD, cynomolgus B7-H1 shares 92%, 72%, and 72% aa sequence identity with human, mouse, and rat B7-H1, respectively. In addition cynomolgus B7-H1 shares 98%, 94%, 94%, 88%, 78%, 98%, 95%, 94%, and 94% aa sequence identity with rhesus macaque, chimpanzee, sumatran orangutan, white-tufted-ear marmoset, Garnett's greater bushbaby, olive baboon, green monkey, western lowland gorilla, and northern white-cheeked gibbon B7-H1, respectively. B7-H1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (3-6), keratinocytes (7, 8), endothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (10, 11). B7-H1 is a B7 ligand and binds to B7-1/CD80 and PD-1 receptors on T cells (6, 7, 11-14). It suppresses T cell activation and proliferation (4, 7, 13, 15) and induces the apoptosis of activated Tcells (10). It plays a role in the development of immune tolerance by promoting T cell anergy (6, 13) and enhancing regulatory T cell development (15). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (4, 9) and inhibits the development of Th17 cells (15). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (5, 8, 11, 14). B7-H1/PD-1 coinhibitory pathway was exploited therapeutically resulting in remarkable outcomes with 20-90% response in various types of cancer (16).

Related Research Areas

• Co-stimulatory and Co-inhibitory Molecules
• Co-stimulatory Molecules Associated with Tfh Cells
• Epithelial Cell Markers and Intracellular Molecules
• Myeloid-derived Suppressor Cells (MDSC)
• Regulatory T Cells (Tregs)
• Search Immune Checkpoint Targets
• Surface Ectodermal Cells